samedi 10 octobre 2026
RechercherExplore
fr.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 9, 2026

Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica

View original at finance.yahoo.com
Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica AstuteAnalytica India Pvt…
Opening lines of the source · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • North America's leadership in life sciences analytics stems from strong research infrastructure, extensive clinical trials, and a concentration of top-tier academic institutions

    80% confidence

  • Leading players such as Roche, Johnson & Johnson, AstraZeneca, and Merck are investing heavily in specialized analytics tools and dedicated data teams to accelerate real-time decision-making, improve patient stratification, and enhance treatment outcomes

    80% confidence

  • The global life sciences analytics market was valued at 11.10 billion in 2024 and is expected to reach US$ 23.17 billion by 2033, growing at a CAGR of 8.52% from 2025 to 2033

    80% confidence

  • Growth is fueled by the adoption of advanced analytics platforms, AI-driven modules, and cloud-based solutions that optimize drug discovery, clinical trials, pharmacovigilance, and precision medicine

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Notre lecture des données ›
Signaux que nous suivons
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Tendances que nous surveillons ›
Là où les sources divergent
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,986
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,986 faits vérifiés avec la source5,365 documents sources archivés
Interrogez ces données → isubstrate.com